Summary auto-generated
Researchers tested a large panel of chemokines (immune signaling proteins) to determine their effects on HIV-1 replication in cultured CD4+ T cells. While most chemokines had no significant effect, the study confirmed that RANTES, MIP-1α, and MIP-1β inhibit HIV replication, and identified MCP-2 and lymphotactin as additional chemokines with anti-HIV activity. However, higher concentrations (≥250 ng/ml) were generally required compared to RANTES and related chemokines. Interestingly, MCP-3 and macrophage-derived chemokine (MDC) actually enhanced viral replication at certain concentrations, contrary to some previous reports. The researchers also demonstrated that chemokines can interact antagonistically: when non-inhibitory chemokines were combined with inhibitory ones like RANTES or MCP-2, the antiviral effects were reduced. These findings suggest that chemokine-mediated HIV suppression depends on specific receptor interactions and chemokine concentrations, with potential implications for developing chemokine-based antiviral therapies.
Key findings
- MCP-2 and lymphotactin showed consistent inhibition of HIV replication, with MCP-2 particularly effective against non-syncytium-inducing (NSI) virus isolates
- MCP-3 and macrophage-derived chemokine (MDC) enhanced rather than inhibited HIV replication at certain concentrations, contradicting previous reports
- Chemokines demonstrated antagonistic effects when combined: non-inhibitory chemokines could block the anti-HIV activity of RANTES and MCP-2
- Most chemokines in the tested panel had no substantial effect on HIV replication, and effective chemokines typically required concentrations higher than physiological levels
This summary was generated automatically from the article PDF and is not part of the original publication. Refer to the PDF for the authoritative text.
Abstract
Examination of a large panel of chemokines indicates that in addition to RANTES, MIP-1α and MIP-1ß, the ß-chemokine MCP-2 and, to a lesser extent, the γ-chemokine lymphotactin also show anti-human immunodeficiency virus (HIV) activity in cell culture. The amount of chemokine needed to suppress HIV replication by 50% was generally greater (250 ng/ml) than that required for inhibition of virus infection by RANTES, MIP-1α and MIP-1ß. The ß-chemokine MCP-3 was found to enhance the replication of both non-syncytium-inducing (NSI) and syncytium-inducing (SI) viruses at high concentrations (0·55 µg/ml). In contrast to a previous report, macrophage-derived chemokine was not found to inhibit HIV replication of either NSI or SI viruses, but at low concentrations enhanced NSI virus replication. When small amounts of RANTES or MCP-2 were added together with high concentrations of non-inhibitory chemokines, the anti-HIV effects were countered. Information on chemokines that affect HIV infection could be useful for future therapeutic strategies.